EU Drug Supply In Jeopardy Without Energy Support, Warns Medicines For Europe
Industry Body Raises The Alarm Over Energy Costs In Open Letter
Medicines for Europe calls for the pharmaceutical industry to be excluded from energy restriction policies for winter 2022 in an open letter to EU governance bodies. Inflation and energy costs threaten European drug makers with closures and rationing, says the industry body.
You may also be interested in...
As the antibiotics market recovers in the wake of the COVID-19 pandemic, Centrient CEO Rex Clements talks to Generics Bulletin about the firm’s recent sustainability milestones as well as the cost and policy challenges faced by European manufacturing.
The joint action on ensuring security of medicines supply will be supported by the EU regulators’ shortages task force, which is to track efforts to coordinate member state activities on the supply and availability of medicines.
Rising energy costs, challenges in accessing supplies and rapidly changing technology are all factors that mean industry needs a certain and established regulatory structure to help it cope.